纳米探针
肝细胞癌
体内
癌症研究
光热治疗
药物输送
磁共振成像
化学
介孔二氧化硅
纳米技术
体外
靶向给药
肝癌
药品
材料科学
肿瘤微环境
纳米颗粒
毒品携带者
癌细胞
生物相容性
作者
Ying Cao,Xiaorong Zhu,Yuqi Li,Liguo Hao,Yuguang Wang,Mengjiao Wang,Xiaoyang Yu,Xiao Wang,Yuyi Wang,Haifeng Hu
标识
DOI:10.1021/acsanm.6c00575
摘要
Chemotherapy remains a standard treatment for hepatocellular carcinoma (HCC). Nevertheless, the complexity of the tumor microenvironment (TME) significantly reduces the efficiency of drug delivery and penetration into tumor tissues. Nanosized probes exhibit unique advantages in passive targeting via the enhanced permeability and retention (EPR) effect, enabling efficient identification, deep-tissue imaging and targeted drug transport for HCC management. In this study, an magnetic resonance-fluorescence bimodal imaging nanoprobe with a well-defined nanoscale structure (≈190 nm hydrodynamic diameter), designated cRGD-MnO 2 / [email protected] (cHMDPC), was developed for HCC precision theranostics. This nanostructured platform is responsive to the TME, exhibits specific targeting, enhances contrast in T1-weighted magnetic resonance imaging (MRI), and has photothermal properties that act synergistically with chemotherapy, improving antitumor efficacy. In vitro studies demonstrated that cHMDPC nanoprobes were more effectively internalized by HCC cells, indicating strong targeting specificity. This nanoprobe markedly suppressed cell proliferation and promoted apoptosis. In vivo experiments further confirmed its excellent MRI performance, significant tumor suppression, and high biocompatibility. In summary, the cHMDPC nanoprobe achieves targeted drug delivery, facilitates early diagnosis, and enhances treatment outcomes, providing a novel strategy for HCC theranostics.
科研通智能强力驱动
Strongly Powered by AbleSci AI